Soleo Health, a provider of specialty infusion services, has been chosen by Shire, a global biotechnology company focused on rare diseases, as a provider of the specialty drug Vonvendi. [von Willebrand factor (Recombinant)].
Vonvendi is the first and only recombinant von Willebrand factor (rVWF or VWF), designed specifically for treating and managing adults with von Willebrand disease (VWD), the most common bleeding disorder today, which occurs when blood does not clot properly. VWD affects up to one percent of the world’s population[1], and many people are not accurately diagnosed.
VWD is caused by a deficiency or dysfunction of VWF, one of several types of proteins in the blood needed to facilitate proper blood clotting, resulting in impaired blood clotting, and it affects women and men equally.[2][3] Vonvendi works similarly to the body’s naturally occurring VWF, is administered intravenously to replace missing or dysfunctional VWF, and is indicated to treat and control of bleeding episodes and prevent excessive bleeding before and after surgery. Research shows that as many as 9 out of 10 people with VWD have not been diagnosed.[4]
Soleo Health was selected as a specialty drug distribution provider of vonvendi based on the company’s dedicated bleeding disorders program with deep clinical knowledge and broad expertise in treating and clinically managing those with bleeding disorders, including VWD. Soleo Health’s clinical and patient advocacy teams have undergone extensive training and education with respect to the dispensing, clinical management, and patient support for those receiving Vonvendi.
___________________________________________________________
References:
1. James PD, Goodeve AC. von Willebrand Disease. Genet Med. 2011;13(5):365-76.
2. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
3. Leebeek FW, Eikenboom JC. Von Willebrand’s Disease. N Engl J Med. 2016;375(21):2067-2080.
4. What is von Willebrand disease (VWD)? World Federation of Hemophilia website. https://www.wfh.org/en/page.aspx?pid=673. Accessed May 3, 2017.
(Source: Soleo Health)
